Excerpt from "PEPFAR Vietnam COP REPORT FY 2010"
PEPFAR relies on the availability of generic medicines for its treatment programs in Vietnam, as illustrated in the following excerpt from page 13 of the "PEPFAR Vietnam COP REPORT FY 2010." The report cites Abbott Labs' brand-name lopinavir/ritonavir as a key driver of costs.
For the full report, go here (links to pepfar.gov).
"In recent years, there have been several dramatic improvements in how ARVs are procured and distributed. Permission to import FDA tentatively-approved generic drugs in 2006 led to faster delivery and significantly reduced prices. While the rate of price reductions has slowed, the downward trend continued through 2009. Low-cost ARVs meant that PEPFAR has continued to provide treatment to patients not only at PEPFAR sites but also at sites funded by the government and the Global Fund. PEPFAR is the only program procuring second-line drugs in Vietnam and these are being supplied to all sites prescribing ART. Coordination of procurement continues to improve. (...) Hopes that the cost of second-line treatments would fall significantly have not been realized. Second-line generic medicines have only marginally reduced the cost of second-line treatments; they are still nearly 10 times the cost of first-line medicines. A key driver is the cost of Abbott Lopinavir/Ritonavir products. Expectations that the cost of Lopinavir/Ritonavir would fall by 50% in 2009 due to the introduction of generic versions were dashed when it was discovered that Abbott has patents pending in Vietnam and that Abbott intended to use the patents to prevent the procurement of generic alternatives. Work is continuing with intellectual property experts and VAAC to determine if there are any legal grounds to enable the procurement of generic Lopinavir/Ritonavir. Approximately 98% of ARVs imported for PEPFAR by volume between May 2008 and April 2009 were generics from India. Because of the high price of Abbott Aluvia drugs in particular, and innovator brand drugs in general, these drugs make up 14% of the PEPFAR ARV budget."
For the Trans-Pacific FTA Vietnam Country Page, click here.
For the Kaletra Campaign Vietnam Country Page, click here.